Introduction: Histoplasma capsulatum is a fungus endemic to the Ohio and Mississippi River valleys that can cause pulmonary illness or disseminated infection. There are several tests for histoplasmosis, but serum and urine antigen (UAg, SAg) detection by enzyme-linked immunosorbent assay (ELISA) is most commonly performed due to its speed and accuracy. Studies have shown that UAg detection has higher sensitivity than SAg detection. Methods: At our hospital, UAg detection alone is usually ordered as an initial screen. However, SAg detection is ordered instead or in addition to UAg detection in some instances. The goal of this retrospective analysis was to determine whether SAg detection plays a useful role in the initial evaluation of a patient with suspected histoplasmosis. Results: From 1997 From -2016 UAg and 1,426 SAg tests were performed. From this data, we collected results from pairs of UAg and SAg tests completed on a patient within the same week (ie, paired specimens). Of 615 total paired specimens, 555 were concurrent negatives and 49 were concurrent positives, yielding 98% agreement between UAg and SAg detection. Eight of the 11 remaining paired specimens with discrepant UAg/SAg findings had available medical records. Based on infectious disease consult notes, culture data, and other patient data, we assigned six cases of UAg false positivity, one case of true positivity, and one case of false negativity. Conclusion: In the context of other studies, these findings support the use of UAg detection alone when first testing for suspected histoplasmosis. This aligns with the current practice of most physicians. Furthermore, this study indicates that SAg detection should be performed when a positive UAg result warrants confirmation, rather than as part of an initial screen. Objectives: Ulipristal acetate (UPA) is an oral selective progesterone-receptor modulator (SPRM). VENUS I (NCT02147197) was a phase 3, randomized, double-blind, placebo-controlled study assessing UPA for treatment of uterine fibroids (UF), which included a large proportion of black (self-identified) and obese (BMI ≥30 kg/m 2 ) patients. Methods: This study included a screening period, one 12-week treatment course, and a 12-week drug-free follow-up period. During treatment, premenopausal women (18-50 years) with ≥1 UF and cyclic excessive bleeding were randomized to receive once-daily UPA 5 mg, UPA 10 mg, or placebo. Endometrial thickness was assessed via transvaginal ultrasound. Endometrial biopsies were evaluated at baseline, mid treatment, and by the end of the follow-up period for malignancy and SPRM-associated endometrial changes (PAEC), defined as non-physiologic epithelial changes, extensive cysts, or vascular changes as assessed by three independent pathologists. Results: Of 157 patients randomized, 68.8% were black, and 50.3% were obese. Mean endometrial thickness (mm) at end of treatment (EoT) was similar for black (n = 75) vs non-black (n = 35) patients: UPA 5 mg (11.6 for both), UPA 10 mg (13.0 vs 12.2), placebo (11.0 vs 13.2); and for obese (n = 53) vs non-obese (n = 57) patients: 5 mg (11.9 vs 11.4), 10 mg (13.6 vs 11.9), placebo (10.7 vs 12.4). No evidence of malignancy was observed in endometrial biopsies. One case of hyperplasia without atypia was seen at EoT (black, obese patient; 10 mg), which resolved by end of follow-up. The overall number of patients with PAEC did not increase from baseline to EoT in any treatment group by race or by BMI. Conclusion: In this first US-based phase 3 study of UPA, there was no increase in patients with PAEC in any group (race, BMI). Acknowledging the small subgroup sample sizes, UPA was shown to be a safe treatment option for UF, regardless of race and BMI. Introduction: Oral biotin supplements taken by patients for various inherited metabolic diseases, demyelinating diseases, or to enhance hair and nail growth, can interfere with certain streptavidin-biotin-based immunoassays, as previously described for certain thyroid function tests. Such interference may cause false-positive (over-estimation) and false-negative (under-estimation) results in competitive and non-competitive immunoassays, respectively. Objective: We investigated the effect of biotin interference in two streptavidin-biotin-based, serologic assays, VITROS Hepatitis B e antigen (HBeAg) and VITROS Hepatitis B e antibodies (anti-Hbe; Ortho-Clinical Diagnostics). Methods: HBeAg and anti-HBe are noncompetitive and competitive immunoassays, respectively, and both were performed with the fully automated VITROS ECi Immunodiagnostic System (Ortho-Clinical Diagnostics). Aliquots of serum were prepared from pooled clinical specimens with three different signal/cutoff (S/CO) ratios, 0.21 (negative), 32.4 (reactive), and 2,220 (reactive) for HBeAg; and cutoff/signal (CO/S) ratios, 0.18 (negative), 2.59 (reactive), and 26.6 (reactive) for anti-HBe. These aliquots were spiked with a 0.9% NaCl solution containing 10,000 ng/mL biotin (Sigma-Aldrich) to achieve final biotin concentrations of 0, 10, 50, 100, 500, and 1,000 ng/mL, and were tested in duplicate for HBeAg and anti-HBe. A difference of >14% between observed and expected S/CO or CO/S ratios was considered significant change, based on manufacturer's precision data for these two assays. Results: HBeAg and anti-HBe immunoassays exhibited significant increases of observed S/CO and CO/S, respectively, ranging from 15% to 99% for HBeAg and from 17% to >1,000% for anti-HBe, at the biotin concentrations evaluated. Significant changes in qualitative interpretative results were observed in HBeAg-reactive and anti-HBe-negative serum samples.
Conclusion:
The VITROS HBeAg and anti-HBe immunoassays are susceptible to biotin interference, leading to a clinically significant change in qualitative interpretive results of originally borderline HBeAg-reactive and originally anti-HBe-negative specimens. Clinical laboratories should recognize that the patient's use of biotin-containing supplements might adversely affect certain laboratory test results.
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Diagnosis of Trichomoniasis in Men by Urine Cytology: Epidemiologic and Clinical Implications
Arslan Ahmad, MD, Derek Laskar, MD, Alejandro Zuretti, MD; 1 SUNY Downstate Health Science Center, Brooklyn, NY Background: Trichomoniasis is the most prevalent non-viral sexually transmitted infection worldwide. It is caused by the protozoan Trichomonas vaginalis, and the estimated global incidence is over 170 million cases per year, with over 8 million new cases per year in the United States alone. Up to 70% affected are asymptomatic; when symptoms do occur, dysuria, dyspareunia, urethritis, and vaginitis can be observed. Additionally, women are affected at higher rates than men. Despite the relative large overall annual incidence, very few reports have described the characteristics of male patients with T. vaginalis organisms on cytology. Method: We sought to determine the incidence and clinical significance of this finding in the urine cytology of male patients at our medium-sized academic medical center located in a major urban area. We retrospectively reviewed our archived urine cytology slides that reported T. vaginalis organisms spanning a 15-year period. Clinical histories from men with Trichomonas-positive urine were also reviewed and correlated. Slides were reviewed, and the morphologic characteristics of the organisms were recorded. Results: T. vaginalis were detected in nine of 5,094 urine cytology specimens (0.1%). The patients included six women and three men. The age range for men with Trichomonas-positive urine was from 29 to 52 years (mean age, 44 years; median age, 51 years). On cytologic review, T. vaginalis organisms were pear-shaped, oval, or round; they had cyanophilic staining with often evident eosinophilic cytoplasmic granules; there were pale nuclei; and eccentrically located flagella occasionally observed. Acute inflammation was observed in two of three cases. Clinical history was available in three of three men. Lower urinary tract symptoms were reported in three of three men, most commonly hematuria.
